Acylphosphatase 2 (ACYP2) Genotyping
ACYP2 (Acylphosphatase 2) is a phosphoenzyme hydrolyzing enzyme coded by the ACYP2 gene located at 2p16.2. The enzyme comprises two isoforms: muscle-type (MT) and erythrocyte type (ET). This phosphatase can hydrolyze the phosphoenzyme intermediate of different membrane pumps with potential effects on Ca2+ homeostasis. The enzyme is expressed in the muscle, erythrocytes and in the cochlea where it may play a role in hair cell development or damage.
Genetic mutations in this gene may result in diminished enzyme function. Variants in the gene are associated with a variety of cancers including gastrointestinal, hematopoietic, and hepatic tissue, although variant testing has no role in the diagnosis or treatment of these neoplasms. Furthermore, variants are shown to be associated with cisplatin-induced ototoxicity. Studies in both children and adults with cancer who were treated with cisplatin-based regimens reported a significant association with an intronic variant in the ACYP2 gene rs1872328 and increased risk of cisplatin-induced ototoxicity.
Cisplatin is one of the most widely used platinum-based antineoplastic agents for treatment of various forms of cancer, including solid tumor and hematological malignancies, in both children and adults. A complication that limits the use of this drug is ototoxicity which manifests variably severe and potentially permanent hearing loss. Studies in children have shown association of the ACYP2 rs1872328 and cisplatin-induced ototoxicity with carriers of the minor allele A having an increased risk compared to non-carriers. Similar findings were also published by the pharmacogenetics studies, where the ACYP2 rs1872328 and cisplatin was associated with hearing loss in adults. Children are typically monitored via audiometry during therapy to detect high frequency hearing impairment requiring dosage adjustment. There are currently no recommendations for variant gene testing prior to initiating cisplatin therapy.
- Used in monitoring the toxicity of cisplatin chemotherapy drug for treatment of cancer
- Aids in predicting the toxic response to cisplatin in patients with irreversible hearing loss
A positive result for ACYP2 rs1872328 variant indicates susceptibility to cancers and cisplatin-toxicity.
A negative result for ACYP2 rs1872328 variant indicates lower susceptibility to cisplatin-toxicity, however, doesn’t rule out the risk susceptibility.
ACYP2 rs1872328 G/G Normal metabolizer (Normal risk of cisplatin-induced hearing loss)
Whole Blood, EDTA.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: unstable
- Nat Genet. 2015 Mar;47(3):263-6. [PMID: 25665007]
- Pharmacogenet Genomics. 2016 May;26(5):243-7. [PMID: 26928270]
- Pharmacogenet Genomics. 2017 Jun;27(6):213-222. [PMID: 28445188]
- Mol Genet Genomic Med. 2019 Jul;7(7):e00716. [PMID: 31124313]
- J Exp Clin Cancer Res. 2020 Jun 9;39(1):106. [PMID: 32517717]
- Mol Genet Genomic Med. 2019 Jul;7(7):e00700. [PMID: 31070019]